186 related articles for article (PubMed ID: 33672349)
21. Persistence of Integrase-Deficient Lentiviral Vectors Correlates with the Induction of STING-Independent CD8
Cousin C; Oberkampf M; Felix T; Rosenbaum P; Weil R; Fabrega S; Morante V; Negri D; Cara A; Dadaglio G; Leclerc C
Cell Rep; 2019 Jan; 26(5):1242-1257.e7. PubMed ID: 30699352
[TBL] [Abstract][Full Text] [Related]
22. Transient Expression of Green Fluorescent Protein in Integrase-Defective Lentiviral Vector-Transduced 293T Cell Line.
Nordin F; Hamid ZA; Chan L; Farzaneh F; Hamid MK
Methods Mol Biol; 2016; 1448():159-73. PubMed ID: 27317180
[TBL] [Abstract][Full Text] [Related]
23. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma.
Bellone M; Cantarella D; Castiglioni P; Crosti MC; Ronchetti A; Moro M; Garancini MP; Casorati G; Dellabona P
J Immunol; 2000 Sep; 165(5):2651-6. PubMed ID: 10946294
[TBL] [Abstract][Full Text] [Related]
24. Transduction of human antigen-presenting cells with integrase-defective lentiviral vector enables functional expansion of primed antigen-specific CD8(+) T cells.
Negri DR; Bona R; Michelini Z; Leone P; Macchia I; Klotman ME; Salvatore M; Cara A
Hum Gene Ther; 2010 Aug; 21(8):1029-35. PubMed ID: 20210625
[TBL] [Abstract][Full Text] [Related]
25. Cytomegalovirus-based cancer vaccines expressing TRP2 induce rejection of melanoma in mice.
Xu G; Smith T; Grey F; Hill AB
Biochem Biophys Res Commun; 2013 Jul; 437(2):287-91. PubMed ID: 23811402
[TBL] [Abstract][Full Text] [Related]
26. Rational design of Polymeric Hybrid Micelles to Overcome Lymphatic and Intracellular Delivery Barriers in Cancer Immunotherapy.
Li H; Li Y; Wang X; Hou Y; Hong X; Gong T; Zhang Z; Sun X
Theranostics; 2017; 7(18):4383-4398. PubMed ID: 29158834
[TBL] [Abstract][Full Text] [Related]
27. A Protocol for the Production of Integrase-deficient Lentiviral Vectors for CRISPR/Cas9-mediated Gene Knockout in Dividing Cells.
Vijayraghavan S; Kantor B
J Vis Exp; 2017 Dec; (130):. PubMed ID: 29286484
[TBL] [Abstract][Full Text] [Related]
28. Genetic immunization of mice with human tyrosinase-related protein 2: implications for the immunotherapy of melanoma.
Steitz J; Brück J; Steinbrink K; Enk A; Knop J; Tüting T
Int J Cancer; 2000 Apr; 86(1):89-94. PubMed ID: 10728600
[TBL] [Abstract][Full Text] [Related]
29. An indoleamine 2, 3-dioxygenase siRNA nanoparticle-coated and Trp2-displayed recombinant yeast vaccine inhibits melanoma tumor growth in mice.
Liu DQ; Lu S; Zhang LX; Ji M; Liu SY; Wang SW; Liu RT
J Control Release; 2018 Mar; 273():1-12. PubMed ID: 29355622
[TBL] [Abstract][Full Text] [Related]
30. Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant.
Yamano T; Kaneda Y; Huang S; Hiramatsu SH; Hoon DS
Mol Ther; 2006 Jan; 13(1):194-202. PubMed ID: 16112911
[TBL] [Abstract][Full Text] [Related]
31. Nonintegrating lentiviral vectors can effectively deliver ovalbumin antigen for induction of antitumor immunity.
Hu B; Yang H; Dai B; Tai A; Wang P
Hum Gene Ther; 2009 Dec; 20(12):1652-64. PubMed ID: 19663564
[TBL] [Abstract][Full Text] [Related]
32. Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes.
Perricone MA; Smith KA; Claussen KA; Plog MS; Hempel DM; Roberts BL; St George JA; Kaplan JM
J Immunother; 2004; 27(4):273-81. PubMed ID: 15235388
[TBL] [Abstract][Full Text] [Related]
33. Placenta-specific gene activation and inactivation using integrase-defective lentiviral vectors with the Cre/LoxP system.
Morioka Y; Isotani A; Oshima RG; Okabe M; Ikawa M
Genesis; 2009 Dec; 47(12):793-8. PubMed ID: 19830817
[TBL] [Abstract][Full Text] [Related]
34. Central nervous system tumor immunity generated by a recombinant listeria monocytogenes vaccine targeting tyrosinase related protein-2 and real-time imaging of intracranial tumor burden.
Prins RM; Bruhn KW; Craft N; Lin JW; Kim CH; Odesa SK; Miller JF; Liau LM
Neurosurgery; 2006 Jan; 58(1):169-78; discussion 169-78. PubMed ID: 16385341
[TBL] [Abstract][Full Text] [Related]
35. Synthetic TRP2 long-peptide and α-galactosylceramide formulated into cationic liposomes elicit CD8+ T-cell responses and prevent tumour progression.
Neumann S; Young K; Compton B; Anderson R; Painter G; Hook S
Vaccine; 2015 Oct; 33(43):5838-5844. PubMed ID: 26363382
[TBL] [Abstract][Full Text] [Related]
36. Development and Preclinical Evaluation of an Integrase Defective Lentiviral Vector Vaccine Expressing the HIVACAT T Cell Immunogen in Mice.
Gallinaro A; Borghi M; Pirillo MF; Cecchetti S; Bona R; Canitano A; Michelini Z; Di Virgilio A; Olvera A; Brander C; Negri D; Cara A
Mol Ther Methods Clin Dev; 2020 Jun; 17():418-428. PubMed ID: 32154327
[TBL] [Abstract][Full Text] [Related]
37. Lentiviral vector-mediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines.
Koya RC; Kimura T; Ribas A; Rozengurt N; Lawson GW; Faure-Kumar E; Wang HJ; Herschman H; Kasahara N; Stripecke R
Mol Ther; 2007 May; 15(5):971-80. PubMed ID: 17375074
[TBL] [Abstract][Full Text] [Related]
38. Immunogene therapy for murine melanoma using recombinant adenoviral vectors expressing melanoma-associated antigens.
Perricone MA; Claussen KA; Smith KA; Kaplan JM; Piraino S; Shankara S; Roberts BL
Mol Ther; 2000 Mar; 1(3):275-84. PubMed ID: 10933943
[TBL] [Abstract][Full Text] [Related]
39. Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity.
He Y; Zhang J; Mi Z; Robbins P; Falo LD
J Immunol; 2005 Mar; 174(6):3808-17. PubMed ID: 15749922
[TBL] [Abstract][Full Text] [Related]
40. Targeted gene modification in mouse ES cells using integrase-defective lentiviral vectors.
Okada Y; Ueshin Y; Hasuwa H; Takumi K; Okabe M; Ikawa M
Genesis; 2009 Apr; 47(4):217-23. PubMed ID: 19208434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
